Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$144.31

0.08 (0.06%)

, CLVS

Clovis

$59.97

0.27 (0.45%)

10:13
06/19/17
06/19
10:13
06/19/17
10:13

Tesaro worth $80 per share on fundamentals, says Jefferies

Jefferies analyst Eun Yang views Clovis Oncology's (CLVS) data today for rucaparib as "highly competitive" to Tesaro's (TSRO) niraparib. The data from Clovis will likely impact any potential takeover premium for Tesaro, Yang tells investors in a research note. The analyst views Tesaro as being worth $80 per share on a fundamental basis. She has a Hold rating and $124 price target on the shares. Tesaro in early trading is down 5%, or $7.09, to $137.22.

TSRO

Tesaro

$144.31

0.08 (0.06%)

CLVS

Clovis

$59.97

0.27 (0.45%)

  • 30

    Jun

TSRO Tesaro
$144.31

0.08 (0.06%)

06/16/17
FBCO
06/16/17
NO CHANGE
Target $88
FBCO
Outperform
Clovis price target raised to $88 from $74 at Credit Suisse
Credit Suisse analyst Alethia Young assumed coverage of Clovis Oncology (CLVS) and raised the firm's price target on the stock to $88 from $74, noting that her 2023 U.S. estimate for rucaparib is $1.3B versus prior coverage's forecast of $700M. Young, who thinks that the PARPi market is big enough that both Clovis and Tesaro (TSRO) can have blockbuster products, believes both companies are likely attractive targets for large global pharma companies, she tells investors. The analyst keeps an Outperform rating on Clovis shares.
06/19/17
LEER
06/19/17
NO CHANGE
LEER
Outperform
Clovis should now be 'prime takeout candidate,' says Leerink
Leerink analyst Michael Schmidt views this morning's data from Clovis Oncology (CLVS) as the "best-case outcome." The data indicate that efficacy of the three leading PARP inhibitors look very comparable, Schmidt tells investors in a research note titled "Bull Case Plays Out as ARIEL3 Hits All Endpoints." Tesaro (TSRO) and AstraZeneca (AZN) own the other leading PARP inhibitors. The analyst expects shares of Clovis to "trade up significantly" on today's news. Clovis shares in premarket trading are up 40%, or $24.03, to $84.00. "With best-case data in hand," Clovis should be a "prime takeout candidate," Schmidt tells investors. He reiterates an Outperform rating on the shares.
06/19/17
LEER
06/19/17
NO CHANGE
LEER
Market Perform
Clovis reported similar efficacy to Tesaro's Zejula, says Leerink
Leerink analyst Seamus Fernandez says the top-line efficacy data announced this morning for Clovis Oncology's (CLVS) Phase 3 Ariel3 trial of its PARP inhibitor Rubraca "were broadly similar" to that seen in Tesaro's (TSRO) Nova trial of Zejula across all patient population in second-line or greater ovarian cancer maintenance. This adds "considerable weight" to the argument that all three of these PARP inhibitors have similar activity, Fernandez tells investors in a research note. The analyst keeps a Market Perform rating on Tesaro shares.
06/19/17
RAJA
06/19/17
NO CHANGE
RAJA
Market Perform
Raymond James remains cautious on Tesaro, takeout less likely
Raymond James analyst Christopher Raymond remains cautious on Tesaro (TSRO) shares following Clovis' (CLVS) Rubraca ARIEL3 results. The analyst said PFS measures between the Clovis Rubraca and Tesaro's Zejula are remarkably similar among ovarian cancer patients, making the PARP space much more competitive and crowded. Raymond believes a takeout of Tesaro based on Zejula's superior labeling is much less likely and reiterated his Market Perform rating on shares.
CLVS Clovis
$59.97

0.27 (0.45%)

06/19/17
CHDN
06/19/17
UPGRADE
CHDN
Neutral
Clovis upgraded to Neutral from Sell at Chardan
06/19/17
STFL
06/19/17
NO CHANGE
Target $125
STFL
Buy
Clovis price target raised to $125 from $86 at Stifel

TODAY'S FREE FLY STORIES

WLKP

Westlake Chemical Partners

$24.00

0.05 (0.21%)

16:09
09/26/17
09/26
16:09
09/26/17
16:09
Hot Stocks
Westlake Chemical Partners to acquire extra 5% interest in OpCo »

Westlake Chemical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNDC

Landec

$12.55

0.6 (5.02%)

16:08
09/26/17
09/26
16:08
09/26/17
16:08
Earnings
Landec reports Q1 EPS 8c, consensus 6c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

MU

Micron

$34.18

-0.69 (-1.98%)

16:08
09/26/17
09/26
16:08
09/26/17
16:08
Technical Analysis
Technical View: Micron spikes higher after earnings beat »

In the extended session…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MU

Micron

$34.18

-0.69 (-1.98%)

16:07
09/26/17
09/26
16:07
09/26/17
16:07
Hot Stocks
Micron CEO expects healthy industry fundamentals to continue into 2018 »

"Micron delivered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AMSC

AMSC

$4.03

0.01 (0.25%)

16:06
09/26/17
09/26
16:06
09/26/17
16:06
Hot Stocks
AMSC completes acquisition of Infinia Technology »

AMSC announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

16:06
09/26/17
09/26
16:06
09/26/17
16:06
Hot Stocks
Micron says Q4 margin increase due to DRAM products »

Revenues for the fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

GFF

Griffon

$21.55

0.55 (2.62%)

, EMR

Emerson

$63.13

-0.48 (-0.75%)

16:06
09/26/17
09/26
16:06
09/26/17
16:06
Hot Stocks
Griffon amends ClosetMaid purchase agreement »

Griffon Corporation (GFF)…

GFF

Griffon

$21.55

0.55 (2.62%)

EMR

Emerson

$63.13

-0.48 (-0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AVGR

Avinger

$0.21

-0.0211 (-9.13%)

16:04
09/26/17
09/26
16:04
09/26/17
16:04
Hot Stocks
Avinger receives CE Marking approval for in-stent restenosis treatment »

Avinger announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLBD

Blue Bird

$18.85

0.2 (1.07%)

16:03
09/26/17
09/26
16:03
09/26/17
16:03
Hot Stocks
Blue Bird enters stock repurchase agreement with Coliseum Capital »

Blue Bird Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

AMGN

Amgen

$185.60

-0.69 (-0.37%)

, SCR

Simcere

16:03
09/26/17
09/26
16:03
09/26/17
16:03
Hot Stocks
Amgen and Simcere execute agreement to co-develop four biosimilars in China »

Amgen (AMGN) and Simcere…

AMGN

Amgen

$185.60

-0.69 (-0.37%)

SCR

Simcere

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 02

    Dec

  • 03

    Feb

  • 30

    Apr

  • 17

    May

ITCI

Intra-Cellular

16:02
09/26/17
09/26
16:02
09/26/17
16:02
Syndicate
Intra-Cellular files to sell $150M in common stock »

J. P. Morgan Securities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MU

Micron

16:01
09/26/17
09/26
16:01
09/26/17
16:01
Earnings
Micron reports Q4 EPS $2.02 , consensus $1.84 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

SIEGY

Siemens

$68.96

-0.81 (-1.16%)

, ALSMY

Alstom

$3.91

-0.045 (-1.14%)

15:58
09/26/17
09/26
15:58
09/26/17
15:58
Hot Stocks
Siemens, Alstom confirm agreement to combine mobility businesses »

Siemens (SIEGY) and…

SIEGY

Siemens

$68.96

-0.81 (-1.16%)

ALSMY

Alstom

$3.91

-0.045 (-1.14%)

GE

General Electric

$24.97

-0.145 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

HII

Huntington Ingalls

$222.73

2.25 (1.02%)

15:50
09/26/17
09/26
15:50
09/26/17
15:50
Hot Stocks
Huntington Ingalls partners with Ivis to develop compliance software »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$40.93

-1.44 (-3.40%)

15:50
09/26/17
09/26
15:50
09/26/17
15:50
Options
JD options volume is 2.5X daily average and calls outpace puts 4:1 »

JD options volume is 2.5X…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$171.00

-8 (-4.47%)

, INTC

Intel

$37.16

-0.02 (-0.05%)

15:42
09/26/17
09/26
15:42
09/26/17
15:42
Periodicals
Breaking Periodicals news story on Nvidia, Intel, Tesla »

Tesla shifting from…

NVDA

Nvidia

$171.00

-8 (-4.47%)

INTC

Intel

$37.16

-0.02 (-0.05%)

TSLA

Tesla

$344.99

-6.1 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 05

    Oct

  • 08

    Oct

  • 22

    Oct

AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

, TWLO

Twilio

$28.86

-0.615 (-2.09%)

15:38
09/26/17
09/26
15:38
09/26/17
15:38
Hot Stocks
Amazon discussses launch of AWS Global SMS two-way text messaging »

Amazon's (AMZN)…

AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

TWLO

Twilio

$28.86

-0.615 (-2.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 08

    Oct

  • 22

    Oct

LNDC

Landec

$11.95

-0.3 (-2.45%)

15:34
09/26/17
09/26
15:34
09/26/17
15:34
Options
Landec options imply 12.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

T

AT&T

$38.80

-0.32 (-0.82%)

15:30
09/26/17
09/26
15:30
09/26/17
15:30
Periodicals
AT&T's DirecTV to allow 'some' refunds after anthem strife, WSJ says »

Certain subscribers to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Nov

AMJ

American Medical Laboratories Inc

$28.50

0.01 (0.04%)

15:30
09/26/17
09/26
15:30
09/26/17
15:30
Options
Alerian MLP attracts a bullish option play »

Alerian MLP attracts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$85.47

-1.105 (-1.28%)

15:27
09/26/17
09/26
15:27
09/26/17
15:27
Hot Stocks
AbbVie says will take one single digit price increase for 2018 »

AbbVie issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 08

    Nov

STZ

Constellation Brands, also tag STZ.B

$200.37

-0.24 (-0.12%)

15:25
09/26/17
09/26
15:25
09/26/17
15:25
Options
Constellation Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

$NSD

NASDAQ Market Internals

15:17
09/26/17
09/26
15:17
09/26/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
09/26/17
09/26
15:16
09/26/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
09/26/17
09/26
15:15
09/26/17
15:15
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.